SCHEMBL1705899

SCHEMBL1705899

CCCCCC1=C(C=O)CCCC1CO

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 5/20 0.32
SPHK1 Q9NYA1 5/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3823866 0.80 HIF1A (0.31)
SCHEMBL31710677 0.73 SPHK1 (0.33) SPHK2SPHK1
SCHEMBL22470846 0.69
SCHEMBL9446255 0.67 SCD (0.38)
SCHEMBL2212384 0.64 EPHX1 (0.37)
SCHEMBL11807343 0.59 CYP1A2 (0.37)
SCHEMBL4839413 0.59 CYP1A2 (0.39) SPHK1
SCHEMBL13900594 0.58 CYP1A2 (0.44)
SCHEMBL113288 0.58 CYP1A2 (0.44)
SCHEMBL23352536 0.58 NPC1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024033944-A1 FRAGRANCE COMPOSITION AND METHODS THEREOF DABUR INDIA LIMITED (IN) 2024-02-15 WO claimed
US-11390797-B2 Compositions to improve, optimize, or maximize proppant suspension and methods of making and using same NEXTIER COMPLETION SOLUTIONS INC. (US) 2022-07-19 US claimed
CN-110179172-B Consumable for an aerosol-generating device 菲利普莫里斯生产公司 2022-06-24 CN claimed
US-20200354627-A1 COMPOSITIONS TO IMPROVE, OPTIMIZE, OR MAXIMIZE PROPPANT SUSPENSION AND METHODS OF MAKING AND USING SAME NEXTIER COMPLETION SOLUTIONS INC. (US) 2020-11-12 US claimed
EP-1767185-B2 Core shell capsules containing an oil or waxy solid TAKASAGO PERFUMERY CO LTD (JP) 2018-11-28 EP claimed
EP-1767185-B1 Core shell capsules containing an oil or waxy solid TAKASAGO PERFUMERY CO LTD (JP) 2010-10-27 EP claimed
US-20070149424-A1 Perfume for capsule composition TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-06-28 US claimed
EP-1767185-A1 Core shell capsules containing an oil or waxy solid Takasago International Corporation (JP) 2007-03-28 EP claimed
US-20260077021-A1 Compositions and Methods for Treating Endocrine Diseases and Disorders OLFACTIVE AL INC (US) 2026-03-19 US disclosed
US-20250295623-A1 Compositions and Methods for Treating Hypertension by Modulating Endocrine Activity OLFACTIVE AI, INC. 2025-09-25 US disclosed
US-20250213657-A1 Compositions and Methods for Treating Neurodegenerative Diseases and Disorders OLFACTIVE AI, INC. 2025-07-03 US disclosed
US-20250213656-A1 Compositions and Methods for Treating Cardiovascular Diseases and Disorders OLFACTIVE AI, INC. 2025-07-03 US disclosed
US-12290550-B1 Compositions and methods for treating endocrine diseases and disorders OLFACTIVE AI, INC. (US) 2025-05-06 US disclosed
US-12186299-B1 Compositions and methods for treating hypertension by modulating endocrine activity Olfactive Biosolutions, LLC (US) 2025-01-07 US disclosed
US-20050119156-A1 Aromachemicals FLEXITRAL, INC. 2005-06-02 US disclosed
US-20050096852-A1 Method for increasing the stability and intensity of odorant molecules FLEXITRAL, INC. 2005-05-05 US disclosed
WO-2004092182-A1 FRAGRANCE COMPOSITIONS COMPRISING BENZO[4,5]THIENO[3,2-B]PYRAN-2-ONE FLEXITRAL, INC. (US) 2004-10-28 WO disclosed
EP-1458666-A1 IMPROVED AROMACHEMICALS Flexitral Inc. (US) 2004-09-22 EP disclosed
WO-2003053887-A1 A METHOD FOR INCREASING THE STABILITY AND INTENSITY OF ODORANT MOLECULES FLEXITRAL, INC. (US) 2003-07-03 WO disclosed
WO-2003053902-A1 IMPROVED AROMACHEMICALS FLEXITRAL, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077021-A1 Compositions and Methods for Treating Endocrine Diseases and Disorders GLP1R, GIPR, FFAR2 SPHK2 1643/4885SPHK1 1750/4885
US-20050096852-A1 Method for increasing the stability and intensity of odorant molecules OR51E2, OR10J3, ZKSCAN2 SPHK2 1901/4885SPHK1 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.